The Strasbourg, France site is a 65,000 square foot (~6,000 sq. meters) facility of which 35,000 square feet (~3,300 sq. meters) is dedicated for GMP manufacturing.
The facility supports 9 independent synthesis units with solid phase reactors up to 200L and solution phase up to 650L in capacity. The facility has 9 independent purification and isolation suites. Several lyophilizers are available with capacities up to 160 kg of ice.
This site is a development center for new APIs. Its main business is the development, optimization and manufacture of GMP grade peptide APIs for clinical trials and commercial applications. The site is also specialized in the manufacturing of cosmetic peptides
This facility has been regularly inspected by the French Health Products Safety Agency (ANSM) on behalf of the EU. It was also inspected by the US FDA in 2014 in relation to a new commercial product sold in the US and, more recently by the Chinese and Russian authorities.